中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2017, Vol. 39 ›› Issue (2): 236-239.doi: 10.3881/j.issn.1000-503X.2017.02.012

• 论著 • 上一篇    下一篇

淋巴结边缘区淋巴瘤24例临床分析

吕瑞, 易树华, 李增军(), 王婷玉, 刘薇, 李姮, 熊文婕, 邱录贵   

  1. 中国医学科学院 北京协和医学院 血液病医院 血液学研究所淋巴瘤中心,天津 300020
  • 收稿日期:2016-08-17 出版日期:2017-04-20 发布日期:2017-04-20
  • 作者简介:

    通信作者:李增军 电话:022-23909171,电子邮件:zengjunli@163.com

Analysis of Clinical Characteristics for 24 Cases of Nodal Marginal Zone Lymphoma

Rui Lü, Shuhua YI, Zengjun LI(), Tingyu WANG, Wei LIU, Heng LI, Wenjie XIONG, Lugui QIU   

  1. Department of Lymphoma,Institute of Hematology and Blood Disease Hospital,CAMS and PUMC,Tianjin 300020,China
  • Received:2016-08-17 Online:2017-04-20 Published:2017-04-20

摘要:

目的 总结淋巴结边缘区淋巴瘤(NMZL)的临床特点。方法 回顾性分析本院2002年1月至2013年9月淋巴瘤中心住院诊治的NMZL患者,总结临床和实验室检查特点,并对治疗疗效、预后进行统计分析。结果 24例经病理证实的NMZL患者,中位年龄54.4(28~70)岁,男女比例1:1。95%患者存在骨髓受累,乳酸脱氢酶增高40.9%(9/22),丙肝抗体阳性8.3%(2/24),自身抗体阳性33.3%(6/18),单克隆球蛋白阳性率33.3%(8/24)。所有患者CD19、CD20阳性,CD10阴性;CD5阳性率10%(1/10),CD23阳性率50%(5/10),但无CD5/CD23同时阳性患者。治疗总缓解率81.25%,完全缓解率56.2%;应用利妥昔单抗联合化疗较单纯化疗总缓解率及完全缓解率有提高趋势,但差异无统计学意义(P=0.136,P=0.262)。结论 结边缘区淋巴瘤发病率低,男女发病率相当,容易骨髓侵犯;利妥昔单抗较单纯化疗组有可能提高疗效(总缓解率及完全缓解率),甚至有可能改善无进展生存。

关键词: 结边缘区淋巴瘤, 利妥昔单抗, 临床分析

Abstract:

Objective To summarize and investigate the characteristics of nodal marginal zone lymphoma (NMZL). Method The clinical data and laboratory characteristics of of NMZL patients admitted in our hospital between January 2002 and September 2013 were analyzed retrospectively. Results Twenty-four patients were enrolled in the study. The median age was 54.4 (28-70) years,and the male/female ratio was 1:1. Most of the patients (95%) had bone marrow involvement,40.9% (9/22) had elevated lactate dehydrogenase level,8.3% (2/24) had the positive expression of hepatitis C virus antibody,33.3% (6/18) had positive autoimmune antibodies,and 33.3% (8/24) had monoclonal immunoglobulins in the serum. All of the patients expressed CD19 and CD20 cell markers,whereas none of them expressed CD10 cell marker. The positive rate of CD5 marker was 10% (1/10),the positive rate of CD23 marker was 50% (5/10),whereas no patient had the expressions of both CD5 and CD23 at the same time. The total overall remission rate was 81.25%,and the total complete remission rate was 56.2%. The separate overall remission and complete remission rate had increasing trends in rituximab subgroup than subgroups without using rituximab(P=0.136,P=0.262).Conclusion NMZL has a low incidence and can be seen in both males and females. It often invades bone marrow. Rituximab may increase the response rate and even improve the progression free survival.

Key words: nodal marginal zone lymphoma, rituximab, clinical analysis

中图分类号: